PMB trade group balks at move to curtail compension

Federal lawmakers in the USA are pushing for a bill that would limit the structure of how pharmacy benefit managers (PMBs) — companies that operate in between insurers, pharmacists and drugmakers — are paid, although a PBM trade group took issue with the proposed legislation, according to Life Sciences Law360.

The Pharmaceutical Care Management Association (PCMA) released the following statement on legislation introduced by Finance Committee members:

“While we’re currently reviewing the legislation, it’s clear that it fails to address the root cause of high prices and appears to buy into the false rhetoric and self-serving agenda of big drug companies. Drug companies, not pharmacy benefit companies, profit immensely from high list prices they alone set and raise.